Insider selling is routine, small-scale, and follows normal option-exercise patterns, no bearish signal. The broader cluster (13 trades, 7 insiders) is also immaterial at 0.07% of market cap. No short-term action warranted. Monitor next quarterly results for pipeline catalysts, as the 95% bullish analyst consensus and strong institutional ownership (Fidelity, BlackRock) reflect optimism about the drug development pipeline.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 16 $67.71entry
- T+1 · 5mo ago +4.68%α +5.93% · $70.88
- T+5 · 5mo ago +23.17%α +25.40% · $83.40
- T+20 · 4mo ago +29.18%α +28.98% · $87.47
- T+60 · 2mo ago +35.36%α +34.36% · $91.65
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two ORKA insiders, a director and the SVP of Finance, sold $1.01M in open-market shares ($882K of that from director Carl Dambkowski alone) in the past week. However, this selling is dwarfed by a much larger, broader cluster spanning 13 trades by 7 insiders in a 7-day window ending June 15 (including the CEO, CMO, COO, and GC), which includes non-cash derivative exercises and follow-on open-market sales. The aggregate open-market selling of ~$2.9M represents only ~0.07% of market cap and is largely consistent with routine post-vesting liquidity sales following recent option exercises, not a bearish informed signal.
Key Financial Metrics
Key Facts
- Two-insider cluster (Director, SVP Finance) sold ~$1.01M open-market over June 5-12.
- Broader 7-day window includes 13 trades by 7 insiders (CEO, CMO, COO, GC, Director, SVP Finance, other) with $2.9M in open-market sales.
- Director Carl Dambkowski alone sold 35K shares for ~$2.45M (the dominant seller).
- CEO Klein sold $120K, CMO Goncalves sold $112K, COO Sandler sold $42K, GC Quinlan sold $51K.
- Multiple non-cash derivative exercises (options exercised at $0 or $6.84) preceded open-market sales, consistent with sell-to-cover / cashless exercise patterns.
- Total cluster open-market sales ~$2.9M at a $4.2B market cap = only 0.07% of market cap.
- Recent 30-day insider activity (6 sells totaling $480K) matches this pattern, persistent but tiny relative to company size.
- Analyst consensus is 95% bullish (19 Buy, 1 Hold); top holders include Fidelity, BlackRock, and RTW Investments.
Financial Impact
Total open-market sales of ~$2.9M represent approximately 0.07% of $4.2B market cap, a trivial amount.
Risk Factors
- Director Dambkowski sold ~$2.45M aggressively over three days, largest insider seller; worth watching if pattern continues.
- Pre-revenue biopharma risk: stock is driven by clinical data, not insider activity at these trivial levels.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ORKA-1781564346347 |
Track record
40 reports on ORKA
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers